Catalyst Wire Dossier Catalyst Wire Dossier

Bivatuzumab mertansine

bivatuzumab mertansine · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bivatuzumab mertansine, covering 2014-10-01 to 2014-10-01. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus [Phase 1]

See pricing